SCHEMBL2266089

SCHEMBL2266089

CCOc1cc2c(cc1OC)C(c1ccc(OC)nc1OC)=NC1CC(O)CCC21

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.41
PDE4D Q08499 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 1/20 0.41
FPR2 P25090 7/20 0.33
ERN1 O75460 1/20 0.32
MAPK1 P28482 1/20 0.32
CASP1 P29466 1/20 0.32
KDM4E B2RXH2 1/20 0.32
FFAR2 O15552 1/20 0.32
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
CHRM1 P11229 1/20 0.31
PDE3A Q14432 1/20 0.31
NAMPT P43490 1/20 0.31
PDE2A O00408 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15514330 1.00 PDE4A (0.41) PDE4APDE4DPDE4BPDE4CFPR2
SCHEMBL2267064 0.93 PDE4D (0.43) PDE4APDE4DPDE4BPDE4CFPR2
SCHEMBL1411013 0.93 PDE4D (0.43) PDE4APDE4DPDE4BPDE4CFPR2
SCHEMBL14911084 0.93 PDE4D (0.43) PDE4APDE4DPDE4BPDE4CFPR2
SCHEMBL1411375 0.93 PDE4D (0.43) PDE4APDE4DPDE4BPDE4CFPR2
Bromide SCHEMBL1411487 0.92 PDE4D (0.42) PDE4APDE4DPDE4BPDE4CFPR2
Hydrochloric Acid SCHEMBL1411249 0.92 PDE4D (0.42) PDE4APDE4DPDE4BPDE4CFPR2
Hydrochloric Acid SCHEMBL4399120 0.92 PDE4D (0.42) PDE4APDE4DPDE4BPDE4CFPR2
Hydrochloric Acid SCHEMBL4399123 0.92 PDE4D (0.42) PDE4APDE4DPDE4BPDE4CFPR2
Sulfuric Acid SCHEMBL1411894 0.89 PDE4D (0.43) PDE4APDE4DPDE4BPDE4CFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003798-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors NYCOMED GMBH (DE) 2011-08-23 US claimed
US-20080167301-A1 Respiratory system disorders ALTANA PHARMA AG (DE) 2008-07-10 US claimed
EP-1723135-A1 NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-22 EP claimed
WO-2005085225-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO claimed
US-9962377-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors TAKEDA GMBH (DE) 2018-05-08 US disclosed
US-20160279120-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS TAKEDA GMBH (DE) 2016-09-29 US disclosed
EP-2589599-B1 Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors TAKEDA GMBH (DE) 2014-06-25 EP disclosed
US-8455653-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors TAKEDA GMBH (DE) 2013-06-04 US disclosed
EP-2589599-A1 Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors Takeda GmbH (DE) 2013-05-08 EP disclosed
US-20130045974-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2013-02-21 US disclosed
US-8318944-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors NYCOMED GMBH (DE) 2012-11-27 US disclosed
US-20110257169-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2011-10-20 US disclosed
US-8003798-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors NYCOMED GMBH (DE) 2011-08-23 US disclosed
US-20080167301-A1 Respiratory system disorders ALTANA PHARMA AG (DE) 2008-07-10 US disclosed
EP-1723135-A1 NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-22 EP disclosed
WO-2005085225-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045974-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4C PDE4A 1/4885PDE4D 4/4885PDE4B 2/4885
US-20110257169-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4C PDE4A 1/4885PDE4D 4/4885PDE4B 2/4885
US-20160279120-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE12, PDE4B PDE4A 1/4885PDE4D 5/4885PDE4B 3/4885
US-20080167301-A1 Respiratory system disorders PDE4A, PDE4B, PDE12 PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.